17:45 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

Researchers at Northwestern University and colleagues reported data from a Phase III trial in 110 patients with highly active relapsing-remitting multiple sclerosis (MS) showing that conditioning with cyclophosphamide and rabbit anti-thymocyte globulin followed by non-myeloablative...
19:29 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest IFNB1 could help treat breast cancer. In breast tissue samples from patients with invasive ductal carcinoma, levels of IFNB1 were higher in tumors than in...
23:41 , Aug 17, 2017 |  BC Extra  |  Politics & Policy

Representatives investigating rising MS prices

Reps. Elijah Cummings (D-Md.) and Peter Welch (D-Vt.) launched an investigation into the rising price of multiple sclerosis drugs, citing increases in price of as much as 1002% over the lifetime of a drug despite...
07:00 , Aug 17, 2015 |  BioCentury  |  Strategy

Shifting MS spending

Payers are finally getting - and using - the tools to end uninterrupted price increases for multiple sclerosis drugs as a result of an abundance of options, greater willingness to steer prescribing choices, and the...
01:14 , Apr 25, 2015 |  BC Extra  |  Financial News

Pfenex raises $40.5 million in follow-on

Pfenex Inc. (NYSE-M:PFNX) raised $40.5 million through the sale of 2.6 million shares at $15.50 in a follow-on underwritten by Barclays; Evercore; and William Blair. Existing stockholders also sold 3.4 million shares in the offering....
07:00 , Sep 1, 2014 |  BioCentury  |  Strategy

Back to School: Paying the piper

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug...
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
07:00 , Oct 31, 2013 |  BC Innovations  |  Targets & Mechanisms

Benztropine for MS

Although the secondary progressive multiple sclerosis space is filling up with new compounds, few have shown the ability to remyelinate neurons. A new study suggests that an ancient Parkinson's disease drug-benztropine-could accomplish that task in...
07:00 , Sep 2, 2013 |  BioCentury  |  Strategy

Back to School: Facing Reality

BC Staff  For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector,...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Pfenex, Strides Arcolab deal

Strides' Agila Biotech Pvt. Ltd. subsidiary and Pfenex formed a JV to develop and market six biosimilar products worldwide. Agila will hold a 51% equity stake in the JV, but the partners will equally share...